Home › Companies › RECURSION PHARMACEUTICALS, INC. › 2025-2026
Compiled from SEC Form N-PX filings and RECURSION PHARMACEUTICALS, INC.’s Form 8-K, filed June 18, 2026 (Item 5.07 on EDGAR). Page generated November 1, 2026.
Meeting of June 17, 2026: 4 items on RECURSION PHARMACEUTICALS, INC.’s Form 8-K, filed June 18, 2026: 2 elected · 2 approved.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore RECURSION PHARMACEUTICALS, INC. in the interactive database Compare manager voting policies
These tallies are RECURSION PHARMACEUTICALS, INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Najat Khan, Ph.D. | 210,437,751 | -- | -- | 27,907,256 | 126,675,762 | 88% | Elected | — |
| Elect Director: Franziska Michor, Ph.D. | 208,124,737 | -- | -- | 30,220,270 | 126,675,762 | 87% | Elected | — |
| 2. Advisory resolution to approve executive compensation, as disclosed in the Proxy Statement | 206,171,008 | 30,893,147 | 1,280,852 | -- | 126,675,762 | 87% | Approved | — |
| 3. Appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026 | 361,743,500 | 2,148,771 | 1,128,498 | -- | -- | 99.4% | Approved | — |
Source: RECURSION PHARMACEUTICALS, INC., Form 8-K, filed with the SEC on June 18, 2026 — read the filing on EDGAR.
Each item below shows how the 295 asset managers that disclosed a RECURSION PHARMACEUTICALS, INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Najat Khan, Ph.D.
RECURSION PHARMACEUTICALS, INC.’s own tally for this item (“Elect Director: Najat Khan, Ph.D.”): 210,437,751 for, 27,907,256 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, the Company's stockholders voted on the following proposals, each of which is described in more detail in the Company's definitive Proxy Statement for the Annual Meeting filed with the Securities and Exchange Commission on April 30, 2026 (the "Proxy Statement"): Proposal 1: T…”
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 53 asset managers below reported 13,524,020 for, 1,139,490 withheld, 15,336 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,358,442 | 0 | 3 | 0 | For |
| State Street | 1,881,499 | 0 | 0 | 2,160 | For |
| ARK Venture Fund | 620,765 | 0 | 0 | 0 | For |
| BlackRock | 594,714 | 0 | 0 | 0 | For |
| Lincoln Financial | 370,761 | 0 | 0 | 91,230 | Mixed |
| Fidelity | 439,172 | 0 | 0 | 0 | For |
| Charles Schwab | 383,865 | 0 | 0 | 0 | For |
| Equitable | 366,512 | 0 | 0 | 0 | For |
| FundVantage Trust | 0 | 0 | 0 | 311,293 | Withhold |
| Guggenheim | 0 | 0 | 0 | 204,222 | Withhold |
| American Century | 0 | 0 | 0 | 132,750 | Withhold |
| Bridge Builder Trust | 87,100 | 0 | 0 | 0 | For |
| Global X | 78,729 | 0 | 0 | 0 | For |
| SEI | 78,300 | 0 | 0 | 0 | For |
| Themes ETF Trust | 0 | 0 | 0 | 77,000 | Withhold |
| JPMorgan | 66,229 | 0 | 0 | 0 | For |
| DWS | 0 | 0 | 0 | 64,004 | Withhold |
| AMERICAN BEACON FUNDS | 62,666 | 0 | 0 | 0 | For |
| Brighthouse | 0 | 0 | 0 | 58,881 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 43,089 | Withhold |
| Calvert | 0 | 0 | 0 | 37,513 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 37,311 | Withhold |
| ProShares | 0 | 0 | 0 | 35,438 | Withhold |
| Venerable Variable Insurance Trust | 34,542 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 0 | 28,907 | Withhold |
Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.
Combines 5 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Franziska Michor, Ph.D.
RECURSION PHARMACEUTICALS, INC.’s own tally for this item (“Elect Director: Franziska Michor, Ph.D.”): 208,124,737 for, 30,220,270 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, the Company's stockholders voted on the following proposals, each of which is described in more detail in the Company's definitive Proxy Statement for the Annual Meeting filed with the Securities and Exchange Commission on April 30, 2026 (the "Proxy Statement"): Proposal 1: T…”
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 53 asset managers below reported 13,227,070 for, 1,436,440 withheld, 15,336 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,358,442 | 0 | 3 | 0 | For |
| State Street | 1,881,499 | 0 | 0 | 2,160 | For |
| ARK Venture Fund | 620,765 | 0 | 0 | 0 | For |
| BlackRock | 594,714 | 0 | 0 | 0 | For |
| Lincoln Financial | 370,761 | 0 | 0 | 91,230 | Mixed |
| Fidelity | 439,172 | 0 | 0 | 0 | For |
| Charles Schwab | 383,865 | 0 | 0 | 0 | For |
| Equitable | 69,563 | 0 | 0 | 296,949 | Mixed |
| FundVantage Trust | 0 | 0 | 0 | 311,293 | Withhold |
| Guggenheim | 0 | 0 | 0 | 204,222 | Withhold |
| American Century | 0 | 0 | 0 | 132,750 | Withhold |
| Bridge Builder Trust | 87,100 | 0 | 0 | 0 | For |
| Global X | 78,729 | 0 | 0 | 0 | For |
| SEI | 78,300 | 0 | 0 | 0 | For |
| Themes ETF Trust | 0 | 0 | 0 | 77,000 | Withhold |
| JPMorgan | 66,229 | 0 | 0 | 0 | For |
| DWS | 0 | 0 | 0 | 64,004 | Withhold |
| AMERICAN BEACON FUNDS | 62,666 | 0 | 0 | 0 | For |
| Brighthouse | 0 | 0 | 0 | 58,881 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 43,089 | Withhold |
| Calvert | 0 | 0 | 0 | 37,513 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 37,311 | Withhold |
| ProShares | 0 | 0 | 0 | 35,438 | Withhold |
| Venerable Variable Insurance Trust | 34,542 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 0 | 28,907 | Withhold |
Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.
Combines 5 wordings of this item as funds reported it.
87% Approved · of votes cast
Description as filed by funds: ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION AS DISCLOSED IN THE 2026 PROXY STATEMENT.
RECURSION PHARMACEUTICALS, INC.’s own tally for this item (“2. Advisory resolution to approve executive compensation, as disclosed in the Proxy Statement”): 206,171,008 for, 30,893,147 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2: The advisory resolution to approve executive compensation, as disclosed in the Proxy Statement, was approved, with the following votes cast:”
Support: 87% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of RECURSION PHARMACEUTICALS, INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Advisory Vote to Ratify Named Executive Officers' Compensation” (6 managers, 1,570 for, 13,679,273 against).
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,356,830 | 1,616 | 0 | 0 | For |
| State Street | 1,879,098 | 4,561 | 0 | 0 | For |
| ARK Venture Fund | 620,765 | 0 | 0 | 0 | For |
| BlackRock | 594,714 | 0 | 0 | 0 | For |
| Lincoln Financial | 370,761 | 91,230 | 0 | 0 | Mixed |
| Fidelity | 439,172 | 0 | 0 | 0 | For |
| Charles Schwab | 383,865 | 0 | 0 | 0 | For |
| Equitable | 69,563 | 296,949 | 0 | 0 | Mixed |
| FundVantage Trust | 0 | 311,293 | 0 | 0 | Against |
| Guggenheim | 0 | 204,222 | 0 | 0 | Against |
| American Century | 0 | 132,750 | 0 | 0 | Against |
| Investment Managers Series Trust II | 102,692 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 87,100 | 0 | 0 | 0 | For |
| Global X | 78,729 | 0 | 0 | 0 | For |
| SEI | 78,300 | 0 | 0 | 0 | For |
| Themes ETF Trust | 0 | 77,000 | 0 | 0 | Against |
| JPMorgan | 66,229 | 0 | 0 | 0 | For |
| DWS | 0 | 64,004 | 0 | 0 | Against |
| AMERICAN BEACON FUNDS | 62,666 | 0 | 0 | 0 | For |
| Brighthouse | 0 | 14,326 | 44,555 | 0 | Mixed |
| AIG/SunAmerica | 0 | 43,089 | 0 | 0 | Against |
| Calvert | 0 | 37,513 | 0 | 0 | Against |
| Direxion Shares ETF Trust | 0 | 37,311 | 0 | 0 | Against |
| ProShares | 0 | 35,438 | 0 | 0 | Against |
| Venerable Variable Insurance Trust | 34,542 | 0 | 0 | 0 | For |
Fund voting reports, all 54 managers: 13,306,787 for, 1,431,097 against, 44,555 abstained, 1 not voted. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BAILLIE GIFFORD & CO LTD | 20,028,719 | 0 | 0 | 0 | For |
| MIC Capital Management UK LLP | 8,451,758 | 0 | 0 | 0 | For |
| Amova Asset Management Co., Ltd. | 0 | 5,384,024 | 0 | 0 | Against |
| State Street | 5,093,926 | 39,340 | 0 | 0 | For |
| Vanguard | 4,316,134 | 18,935 | 0 | 0 | For |
| Lingotto Investment Management LLP | 4,062,729 | 0 | 0 | 0 | For |
| BlackRock | 3,614,590 | 70,780 | 0 | 0 | For |
| MARSHALL WACE, LLP | 3,064,357 | 0 | 0 | 0 | For |
| ARK Investment Management LLC | 3,034,418 | 0 | 0 | 0 | For |
| Northern Trust | 2,035,454 | 132,271 | 0 | 0 | Mixed |
| Goldman Sachs | 1,009,851 | 53,053 | 0 | 0 | For |
| STIFEL NICOLAUS & CO INC \MO\ | 0 | 945,102 | 0 | 0 | Against |
| Man Group plc | 843,285 | 0 | 0 | 0 | For |
| CAPITAL FUND MANAGEMENT S.A. | 818,892 | 0 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 0 | 762,609 | 0 | 0 | Against |
| Vestmark Advisory Solutions, Inc. | 702,311 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 610,133 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 546,302 | 0 | 0 | Against |
| UBS | 0 | 533,148 | 0 | 0 | Against |
| AllianceBernstein | 0 | 448,204 | 0 | 0 | Against |
| Lazard | 0 | 389,686 | 0 | 0 | Against |
| Charles Schwab | 386,132 | 0 | 0 | 0 | For |
| Allianz | 0 | 340,440 | 0 | 0 | Against |
| Gotham Asset Management, LLC | 0 | 317,188 | 0 | 0 | Against |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 262,465 | 0 | 0 | 0 | For |
Institutional-manager reports, all 247 managers: 61,337,371 for, 12,338,438 against, 2,000 abstained, 4,937 not voted. Showing the 25 largest; see all in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.4% Approved · of votes cast
Description as filed by funds: Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for fiscal year ending December 31, 2026.
RECURSION PHARMACEUTICALS, INC.’s own tally for this item (“3. Appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026”): 361,743,500 for, 2,148,771 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3: The appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026 was ratified, with the following votes cast:”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 55 asset managers below reported 14,739,544 for, 44,555 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,358,445 | 0 | 0 | 0 | For |
| State Street | 1,883,659 | 0 | 0 | 0 | For |
| ARK Venture Fund | 620,765 | 0 | 0 | 0 | For |
| BlackRock | 594,714 | 0 | 0 | 0 | For |
| Lincoln Financial | 461,991 | 0 | 0 | 0 | For |
| Fidelity | 439,172 | 0 | 0 | 0 | For |
| Charles Schwab | 383,865 | 0 | 0 | 0 | For |
| Equitable | 366,512 | 0 | 0 | 0 | For |
| FundVantage Trust | 311,293 | 0 | 0 | 0 | For |
| Guggenheim | 204,222 | 0 | 0 | 0 | For |
| American Century | 132,750 | 0 | 0 | 0 | For |
| Investment Managers Series Trust II | 102,692 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 87,100 | 0 | 0 | 0 | For |
| Global X | 78,729 | 0 | 0 | 0 | For |
| SEI | 78,300 | 0 | 0 | 0 | For |
| Themes ETF Trust | 77,000 | 0 | 0 | 0 | For |
| JPMorgan | 66,229 | 0 | 0 | 0 | For |
| DWS | 64,004 | 0 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 62,666 | 0 | 0 | 0 | For |
| Brighthouse | 14,326 | 0 | 44,555 | 0 | Mixed |
| AIG/SunAmerica | 43,089 | 0 | 0 | 0 | For |
| Calvert | 37,513 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 37,311 | 0 | 0 | 0 | For |
| ProShares | 35,438 | 0 | 0 | 0 | For |
| Venerable Variable Insurance Trust | 34,542 | 0 | 0 | 0 | For |
Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.
Not shown here: this season’s fund filings also report 1 item from the meeting of June 18, 2025, which belongs to the 2024-2025 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 530,628,653 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 1.58% |
| 2 | State Street | 0.35% |
| 3 | ARK Venture Fund | 0.12% |
| 4 | BlackRock | 0.11% |
| 5 | Lincoln Financial | 0.09% |
| 6 | Fidelity | 0.08% |
| 7 | Charles Schwab | 0.07% |
| 8 | Equitable | 0.07% |
| 9 | FundVantage Trust | 0.06% |
| 10 | Guggenheim | 0.04% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BAILLIE GIFFORD & CO LTD | 3.77% |
| 2 | MIC Capital Management UK LLP | 1.59% |
| 3 | Amova Asset Management Co., Ltd. | 1.01% |
| 4 | State Street | 0.97% |
| 5 | Vanguard | 0.82% |
| 6 | Lingotto Investment Management LLP | 0.77% |
| 7 | BlackRock | 0.69% |
| 8 | MARSHALL WACE, LLP | 0.58% |
| 9 | ARK Investment Management LLC | 0.57% |
| 10 | Northern Trust | 0.41% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Vanguard Group | 8.89% | 13F |
| BlackRock | 8.14% | 13F |
| ARK Investment Management LLC | 7.03% | 13G |
| Vanguard Portfolio Management | 5.91% | 13G |
| State Street | 5.37% | 13F |
| BAILLIE GIFFORD & CO | 4.48% | 13G |
| Zachary Bogue | 2.57% | DEF14A |
| Blake Borgeson | 1.20% | DEF14A |
| Goldman Sachs | 1.14% | 13F |
| Morgan Stanley | 1.07% | 13F |
Percentages above are of 530,628,653 shares outstanding, as reported by RECURSION PHARMACEUTICALS, INC. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from RECURSION PHARMACEUTICALS, INC.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 1, 2026; a live search always shows the current data.
At RECURSION PHARMACEUTICALS, INC.'s shareholder meeting held June 17, 2026, in the 2025-2026 proxy season, 295 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 1,054 separate fund positions. On the most widely held item on that ballot — ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION AS DISCLOSED IN THE 2026 PROXY STATEMENT. — RECURSION PHARMACEUTICALS, INC.'s filing reports the proposal as approved, with 87% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: RECURSION PHARMACEUTICALS, INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 18, 2026.
RECURSION PHARMACEUTICALS, INC. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Download data (CSV): ballot items · votes by manager · column guide.